Image-guided locoregional non-intravascular interventional treatments for hepatocellular carcinoma: Current status
Hepatocellular carcinoma (HCC) is one of the most deadly and frequent cancers worldwide, although great advancement in the treatment of this malignancy have been made within the past few decades. It continues to be a major health issue due to an increasing incidence and a poor prognosis. The majorit...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
KeAi Communications Co., Ltd.
2021-02-01
|
Series: | Journal of Interventional Medicine |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2096360220300740 |
id |
doaj-24252b7b56644f83bf489aaffd40581e |
---|---|
record_format |
Article |
spelling |
doaj-24252b7b56644f83bf489aaffd40581e2021-02-13T04:24:04ZengKeAi Communications Co., Ltd.Journal of Interventional Medicine2096-36022021-02-014117Image-guided locoregional non-intravascular interventional treatments for hepatocellular carcinoma: Current statusKun Qian0Feng Zhang1Stephen K. Allison2Chuansheng Zheng3Xiaoming Yang4Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430022, China; Department of Radiology, Image-Guided Biomolecular Intervention Research, University of Washington School of Medicine, Seattle, WA, 98109, USADepartment of Radiology, Image-Guided Biomolecular Intervention Research, University of Washington School of Medicine, Seattle, WA, 98109, USADivision of Interventional Radiology, Department of Radiology, University of Washington School of Medicine, Seattle, WA, 98109, USADepartment of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430022, ChinaDepartment of Radiology, Image-Guided Biomolecular Intervention Research, University of Washington School of Medicine, Seattle, WA, 98109, USA; Division of Interventional Radiology, Department of Radiology, University of Washington School of Medicine, Seattle, WA, 98109, USA; Corresponding author. Department of Radiology, Image-Guided Biomolecular Intervention Research, University of Washington, School of Medicine, 850 Republican Street, Seattle, WA, 98109, USA.Hepatocellular carcinoma (HCC) is one of the most deadly and frequent cancers worldwide, although great advancement in the treatment of this malignancy have been made within the past few decades. It continues to be a major health issue due to an increasing incidence and a poor prognosis. The majority of patients have their HCC diagnosed at an intermediate or advanced stage in theUSA or China. Curative therapy such as surgical resection or liver transplantation is not considered anoption of treatment at these stages.Transarterial chemoembolization (TACE), the most widely used locoregional therapeutic approach, used to be the mainstay of treatment for cases with unresectable cancer entities. However, for those patients with hypovascular tumors or impaired liver function reserve, TACE is a suboptimal treatment option. For example, embolization does not result in complete coverage of a hypovascular tumor, and may rather promotes postoperative tumor recurrence, or leave residual tumor, in these TACE-resistance patients. In addition, TACE carries a higher risk of hepatic decompensation in patients with poor liver function or reserve.Non-vascular interventional locoregional therapies for HCC include radiofrequency ablation (RFA), microwave ablation (MWA), high-intensity focused ultrasound (HIFU), laser-induced thermotherapy (LITT), cryosurgical ablation (CSA), irreversible Electroporation (IRE), percutaneous ethanol injection (PEI), and brachytherapy. Recent advancements in these techniques have significantly improved the treatment efficacy of HCC and expanded the population of patients who qualify for treatment. This review embraces the current status of imaging-guided locoregional non-intravascular interventional treatments for HCCs, with a primary focus on the clinical evaluation and assessment of the efficacy of combined therapies using these interventional techniques.http://www.sciencedirect.com/science/article/pii/S2096360220300740 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Kun Qian Feng Zhang Stephen K. Allison Chuansheng Zheng Xiaoming Yang |
spellingShingle |
Kun Qian Feng Zhang Stephen K. Allison Chuansheng Zheng Xiaoming Yang Image-guided locoregional non-intravascular interventional treatments for hepatocellular carcinoma: Current status Journal of Interventional Medicine |
author_facet |
Kun Qian Feng Zhang Stephen K. Allison Chuansheng Zheng Xiaoming Yang |
author_sort |
Kun Qian |
title |
Image-guided locoregional non-intravascular interventional treatments for hepatocellular carcinoma: Current status |
title_short |
Image-guided locoregional non-intravascular interventional treatments for hepatocellular carcinoma: Current status |
title_full |
Image-guided locoregional non-intravascular interventional treatments for hepatocellular carcinoma: Current status |
title_fullStr |
Image-guided locoregional non-intravascular interventional treatments for hepatocellular carcinoma: Current status |
title_full_unstemmed |
Image-guided locoregional non-intravascular interventional treatments for hepatocellular carcinoma: Current status |
title_sort |
image-guided locoregional non-intravascular interventional treatments for hepatocellular carcinoma: current status |
publisher |
KeAi Communications Co., Ltd. |
series |
Journal of Interventional Medicine |
issn |
2096-3602 |
publishDate |
2021-02-01 |
description |
Hepatocellular carcinoma (HCC) is one of the most deadly and frequent cancers worldwide, although great advancement in the treatment of this malignancy have been made within the past few decades. It continues to be a major health issue due to an increasing incidence and a poor prognosis. The majority of patients have their HCC diagnosed at an intermediate or advanced stage in theUSA or China. Curative therapy such as surgical resection or liver transplantation is not considered anoption of treatment at these stages.Transarterial chemoembolization (TACE), the most widely used locoregional therapeutic approach, used to be the mainstay of treatment for cases with unresectable cancer entities. However, for those patients with hypovascular tumors or impaired liver function reserve, TACE is a suboptimal treatment option. For example, embolization does not result in complete coverage of a hypovascular tumor, and may rather promotes postoperative tumor recurrence, or leave residual tumor, in these TACE-resistance patients. In addition, TACE carries a higher risk of hepatic decompensation in patients with poor liver function or reserve.Non-vascular interventional locoregional therapies for HCC include radiofrequency ablation (RFA), microwave ablation (MWA), high-intensity focused ultrasound (HIFU), laser-induced thermotherapy (LITT), cryosurgical ablation (CSA), irreversible Electroporation (IRE), percutaneous ethanol injection (PEI), and brachytherapy. Recent advancements in these techniques have significantly improved the treatment efficacy of HCC and expanded the population of patients who qualify for treatment. This review embraces the current status of imaging-guided locoregional non-intravascular interventional treatments for HCCs, with a primary focus on the clinical evaluation and assessment of the efficacy of combined therapies using these interventional techniques. |
url |
http://www.sciencedirect.com/science/article/pii/S2096360220300740 |
work_keys_str_mv |
AT kunqian imageguidedlocoregionalnonintravascularinterventionaltreatmentsforhepatocellularcarcinomacurrentstatus AT fengzhang imageguidedlocoregionalnonintravascularinterventionaltreatmentsforhepatocellularcarcinomacurrentstatus AT stephenkallison imageguidedlocoregionalnonintravascularinterventionaltreatmentsforhepatocellularcarcinomacurrentstatus AT chuanshengzheng imageguidedlocoregionalnonintravascularinterventionaltreatmentsforhepatocellularcarcinomacurrentstatus AT xiaomingyang imageguidedlocoregionalnonintravascularinterventionaltreatmentsforhepatocellularcarcinomacurrentstatus |
_version_ |
1724271939031138304 |